To The Moon

Blue Water Vaccines surged 364.44% in its first day of trading.

Blue Water Vaccines, Inc. , a biopharmaceutical company developing vaccines, announced the pricing of its initial public offering of 2,222,222 shares of its common stock at a public offering price of $9.00 per share. The shares begin trading on the Nasdaq Capital Market under the ticker symbol "BWV" on Friday.

Blue Water Vaccines, Inc. is a biopharmaceutical company focused on developing transformational vaccines to address significant health challenges globally. Headquartered in Cincinnati, OH, the company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center (CCHMC), and St. Jude Children's Hospital.

The company is developing a universal flu vaccine that will provide protection from all virulent strains and a Streptococcus pneumoniae (pneumococcus) vaccine candidate, designed to specifically prevent the highly infectious middle ear infections, known as Acute Otitis Media (AOM), in children. Additionally, Blue Water Vaccines has licensed a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from CCHMC to develop vaccines for multiple infectious diseases, including norovirus/rotavirus and malaria among others.